In his weekly clinical update Dr. Griffin discusses a healthcare-associated infection with Monkeypox virus, air and surface sampling for monkeypox virus in a UK hospital, misrepresentation and nonadherence regarding COVID19 public health measures, tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine, clinical, virologic, and immunologic evaluation of symptomatic rebound following Nirmatrelvir/Ritonavir treatment, early outpatient treatment with Eemdesivir in patients at high risk for severe COVID-19, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, and outcomes among confirmed cases and a matched comparison group in the long-COVID in Scotland.
Click arrow to play
Download TWiV 945 (27 MB .mp3, 44 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Research assistant position with Amy Rosenfeld (pdf) 00:35
- Support MicrobeTV with a Spike t-shirt at Vaccinated.US 1:24
- A healthcare-associated infection with monkeypox virus (OFID) 3:30
- Air and surface sampling for monkeypox virus (The Lancet) 6:17
- Misrepresentation & nonadherence in COVID-19 public health measures (JAMA) 13:35
- Tolerability and immunogenicity of a COVID-19 vaccine (The Lancet) 16:47
- PAXLOVID patient eligibility screening checklist (FDA)
- Evaluation of symptomatic disease rebound following PAXLOVID (CID) 21:40
- Outpatient treatment with Remdesivir in patients at high risk (OFID) 29:50
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Molnupiravir as early treatment for adults with COVID-19 (SSRN) 31:37
- Outcomes among confirmed cases and matched comparison group in long-COVID (Nature) 34:04
- Dr. Griffin’s treatment guide (pdf)
- Contribute to Floating Doctors fundraiser at PWB 36:44
- Letters read on TWiV 945 37:01
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Interesting results from chAdox intranasal trial! Lots of preclinical work on ways to drive mucosal immunity to vaccines with chemokine direction either by prime and pull (Iwasaki, many-HSV) or by parenteral delivery of chemokine adjuvant (Gary et al. Cell reports med. 2023- SARS2). Very exciting work, not just got COVID vaccines but vaccines for any mucosal pathogen.